Abstract
Treatment-resistant depression is depression that has not responded well enough to treatment that was given properly. It is most often defined as too little benefit from at least two antidepressants, each taken at a high enough dose for long enough. Researchers still disagree about the exact definition, and some experts prefer the wider idea of difficult-to-treat depression. The condition is common among people treated for depression, and it is linked with lower quality of life and higher costs. It is not the end of the options, because health guidance describes many next steps, from changing medicines to talking therapy and brain stimulation.
Keywords: treatment-resistant depression, difficult-to-treat depression, refractory depression, antidepressants, major depressive disorder
Get Help Now
Anyone who is thinking about suicide or self-harm, or who feels unable to cope, should contact a crisis line straight away. People in immediate danger should call their local emergency number.
- United States: the 988 Suicide & Crisis Lifeline takes calls and texts at 988 (988lifeline.org). - United Kingdom: Samaritans can be called free on 116 123 (samaritans.org). - Canada: the Suicide Crisis Helpline takes calls and texts at 9-8-8 (988.ca). - Australia: Lifeline can be called on 13 11 14 (lifeline.org.au).
What Treatment-Resistant Depression Is
Doctors use the term treatment-resistant depression, often shortened to TRD, when depression has not got better despite earlier treatment (Gaynes et al., 2020). For major depressive disorder, the medical name for clinical depression, the most common definition counts two treatments that did not work (Gaynes et al., 2020). For bipolar disorder, a mood condition that also involves periods of high mood, some definitions count a single failed treatment (Gaynes et al., 2020). The US National Institute of Mental Health describes TRD in terms of at least two antidepressants that have been tried (National Institute of Mental Health, 2024). An international panel of experts, clinicians, regulators and one person with lived experience agreed on a definition for research (Sforzini et al., 2022). Under it, depression counts as treatment resistant after two failed treatments, with symptoms improving by less than 25 percent (Sforzini et al., 2022). The same panel named a middle group, partially responsive depression, for improvement of 25 percent up to just under 50 percent (Sforzini et al., 2022).Even so, the definition is far from settled. One review of studies published in 2016 and 2017 counted 155 different definitions across 150 studies (Brown et al., 2019). That review also found that clinicians rarely use the term in daily care, and that research definitions do not always match clinical use (Brown et al., 2019). A second review found no agreed definition and called for one, together with a shared set of outcomes for future studies (Gaynes et al., 2020). Some experts prefer a broader idea called difficult-to-treat depression (McAllister-Williams et al., 2020). This framework looks at many sides of a person's situation, and it stresses shared decision-making, in which the person and the clinician choose a plan together (McAllister-Williams et al., 2020). Its authors note that it rests mainly on expert agreement and may not be precise enough to define groups for regulatory trials (McAllister-Williams et al., 2020).
Signs That Treatment Is Not Working
The signs of treatment-resistant depression are mostly about how symptoms change, or fail to change, over a course of treatment. Health agencies and researchers point to situations like these:- Symptoms have not improved on an antidepressant, and the NHS notes that a person may respond to one antidepressant but not to another (National Health Service, 2023). - Improvement is only partial, with symptoms easing by less than half (Sforzini et al., 2022). - Two or more treatments have been tried without enough benefit (National Health Service, 2023). - Symptoms come back after a spell of feeling better, which guidance calls relapse and plans to prevent (National Institute for Health and Care Excellence, 2022). - The core symptoms of depression carry on, such as a sad or empty mood for most of the day, little interest in things that used to feel good, tiredness, poor sleep, or trouble thinking clearly (National Institute of Mental Health, 2024).
Other ongoing signs can include feelings of hopelessness, guilt or worthlessness, and changes in appetite or weight (National Institute of Mental Health, 2024). Not everyone has every symptom (National Institute of Mental Health, 2024). Antidepressants also take time to work, and NIMH gives a window of about 4 to 8 weeks (National Institute of Mental Health, 2024). So little change in the first days or weeks is not, on its own, a sign that treatment has failed.
What Counts as an Adequate Trial
A trial, in this sense, means one attempt with one treatment. An adequate trial is one that gave the treatment a fair chance: the dose was high enough, and it was taken for long enough (Gaynes et al., 2020). Experts do not fully agree on what high enough or long enough should mean (Gaynes et al., 2020). The expert panel that wrote the research definition set a time frame of at least four weeks (Sforzini et al., 2022). Some of that panel's points reached only moderate agreement and still need to be confirmed (Sforzini et al., 2022).Researchers also sort resistance into stages or levels. Tools for this include the Thase and Rush Staging Model and the Maudsley Staging Model (Brown et al., 2019). A questionnaire called the Antidepressant Treatment Response Questionnaire is a clinical trial tool used to check assessments of TRD (Brown et al., 2019). Whether a past trial was adequate matters, because a treatment that was never given a fair chance cannot really be said to have failed.
Why Depression May Not Respond
Sometimes depression only looks resistant. A review of 196 articles found that bipolar disorder that had not been spotted may lie behind some apparent cases of TRD (Correa et al., 2010). Groups of people with TRD showed high rates of this hidden bipolar disorder (Correa et al., 2010). The authors judged the support to be at least moderate and suggested screening for bipolarity (Correa et al., 2010). They also noted that the studies they reviewed were not designed to test this idea (Correa et al., 2010).The experts behind the difficult-to-treat framework group the barriers to getting better into three kinds (McAllister-Williams et al., 2020). Some relate to the person, some to the illness, and some to the treatment (McAllister-Williams et al., 2020). Depression in general is linked with a mix of genetic, biological, environmental and psychological factors (National Institute of Mental Health, 2024).
An opinion review added further points. It linked psychosocial factors, and a person's attitude toward medicine, with how well treatment works (Demyttenaere & Van Duppen, 2019). It also linked poorer results to treatment that did not match what the person preferred (Demyttenaere & Van Duppen, 2019). The same review argues that TRD is not one single condition (Demyttenaere & Van Duppen, 2019). None of these findings can explain why a particular person has not improved. That question belongs with the person's own doctor.
How Common It Is and How It Affects Life
Estimates of how many people treated for depression have TRD differ widely, from about 7 percent to 44 percent (Demyttenaere & Van Duppen, 2019). This wide range fits with how differently studies define the condition (Brown et al., 2019; Demyttenaere & Van Duppen, 2019). In one large study, STAR*D, about 47 percent of people responded at the first treatment step (Demyttenaere & Van Duppen, 2019).A review of 62 articles, covering 59,462 patients, gives a picture of what TRD can look like (Mrazek et al., 2014). On average, people with TRD had had about 4 earlier episodes of depression and about 5 medicine trials that did not work (Mrazek et al., 2014). Their quality of life was lower than that of people whose depression had responded to treatment or gone into remission, meaning the symptoms had largely cleared (Mrazek et al., 2014). Their health care costs and their lost working time were also higher (Mrazek et al., 2014). The review set out to describe the burden of TRD in the United States (Mrazek et al., 2014).
A separate review looked at 12 studies of costs and 19 studies of health-related quality of life (Johnston et al., 2019). It found a pattern: the more treatment steps that had not worked, the higher the costs and the lower the quality of life (Johnston et al., 2019). It could not say whether TRD itself causes this burden, and the studies defined TRD in different ways (Johnston et al., 2019). Another review reported a US study in which yearly direct costs were 40 percent higher for TRD than for other depression (Demyttenaere & Van Duppen, 2019). It also described the strain on caregivers and the stigma that people with TRD can face (Demyttenaere & Van Duppen, 2019). Even so, few treatment studies measure daily functioning or quality of life (Gaynes et al., 2020).
What Usually Happens Next
When depression has not responded, guidance describes a range of next steps. In the UK, NICE guidance on depression in adults, NG222, covers treatment-resistant depression along with chronic depression and relapse prevention (National Institute for Health and Care Excellence, 2022). It applies to adults aged 18 and over, and its recommendations are not mandatory (National Institute for Health and Care Excellence, 2022). Looking again at the diagnosis is part of the picture, since experts suggest checking for hidden bipolar disorder (Correa et al., 2010).The NHS describes several treatment options, some of them for depression that has not responded to earlier treatment (National Health Service, 2023):
- moving to a different antidepressant when the first one has not helped; - adding a medicine called mirtazapine to another antidepressant; - trying a medicine called vortioxetine after two antidepressants have not worked; - adding lithium, offered by a specialist after several antidepressants have not helped, which needs regular blood tests; - combining medicine with a talking therapy, which some evidence finds works better than either one alone; - for severe depression, referral to a mental health team that can offer intensive specialist talking treatments; - brain stimulation for severe depression that has not responded to other care.
NIMH notes that some forms of brain stimulation are still experimental (National Institute of Mental Health, 2024). The NHS notes that not everybody benefits from antidepressants and that stopping them can cause withdrawal symptoms (National Health Service, 2023). One review described a trial in which adding long-term psychodynamic psychotherapy to usual care for people with TRD made only slight differences by the end of 18 months of treatment, but showed a benefit 2 years later (Demyttenaere & Van Duppen, 2019). These are options that guidance describes. The choice for any one person is made with that person's doctor.
When to See a Doctor
The NHS says people should contact their GP, meaning their family doctor, straight away if feelings of hopelessness or thoughts of suicide begin or worsen after starting an antidepressant (National Health Service, 2023). The NHS says that improvement should begin in the first 4 weeks on an antidepressant, and that finding one that works can take 2 or more attempts (National Health Service, 2023). Thoughts of death or suicide are among the symptoms of depression that NIMH lists (National Institute of Mental Health, 2024), and anyone having them needs help straight away. A doctor can also help weigh the options, through shared decision-making (McAllister-Williams et al., 2020). Being labelled treatment resistant does not mean that nothing else can be tried, because guidance lists many further steps (National Health Service, 2023).Learn More
More detail is in the full article on treatment-resistant depression. There are also guides to depression symptoms and major depressive disorder symptoms.
Frequently Asked Questions
What does treatment-resistant depression mean? It describes depression that has not improved enough despite earlier treatment. In major depressive disorder, most definitions count two treatments that did not work (Gaynes et al., 2020).Is there one agreed definition?
No. One review found 155 different definitions across 150 studies (Brown et al., 2019).
How long does a treatment need before it counts as a fair trial?
Experts do not fully agree. One international expert panel set a time frame of at least four weeks (Sforzini et al., 2022).
Could the problem be a different condition?
Sometimes. A review found that bipolar disorder that had not been recognised may explain some cases that look like TRD (Correa et al., 2010).
How common is treatment-resistant depression?
Estimates vary a great deal. One review gives a range of about 7 percent to 44 percent of people treated for depression (Demyttenaere & Van Duppen, 2019).
What options can a doctor consider after two antidepressants have not worked?
The NHS describes several treatment options, some of them for depression that has not responded to earlier treatment, including switching or adding medicines, combining medicine with talking therapy, specialist care and, for severe cases, brain stimulation (National Health Service, 2023). NICE guidance says treatment decisions are made in consultation with the person (National Institute for Health and Care Excellence, 2022).
How This Article Was Prepared
This is a plain-language patient guide, not a systematic review. Following medical sourcing guidance, it rests on secondary sources rather than single studies: one clinical guideline, eight reviews of the research and two pages from public health agencies.
- Included: 11 sources, each confirmed against the publisher's or indexer's own record. Six read in full text and five from their abstracts. Agency and guideline pages were read on the publisher's own site. Abstracts came from PubMed and Crossref. - Identifiers: eight references carry a PubMed ID and three a PubMed Central ID, each confirmed by the National Library of Medicine against the cited DOI. - Retractions: eight sources were checked for retractions and editorial notices; none was retracted. - Publication dates: five from the 2010s and six from 2020 or later. - Checked against sources: each of the 70 cited sentences was matched to a passage in its source, and an independent reviewer checked the article against those sources over three passes before publication. - Limits: a short guide summarises selected sources and cannot cover every symptom or situation; it is not a diagnosis or a substitute for seeing a health professional. Each sentence was accepted only after its cited source had been searched for contrary evidence.
See our Editorial Policy for the full method.
References
Brown, S., Rittenbach, K., Cheung, S., McKean, G., MacMaster, F. P., & Clement, F. (2019). Current and common definitions of treatment-resistant depression: Findings from a systematic review and qualitative interviews. Canadian Journal of Psychiatry, 64(6), 380-387. https://doi.org/10.1177/0706743719828965 PMID: 30763119 · PMCID: PMC6591751
Correa, R., Akiskal, H., Gilmer, W., Nierenberg, A. A., Trivedi, M., & Zisook, S. (2010). Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression? Journal of Affective Disorders, 127(1-3), 10-18. https://doi.org/10.1016/j.jad.2010.06.036 PMID: 20655113
Demyttenaere, K., & Van Duppen, Z. (2019). The impact of (the concept of) treatment-resistant depression: An opinion review. International Journal of Neuropsychopharmacology, 22(2), 85-92. https://doi.org/10.1093/ijnp/pyy052 PMID: 29961822 · PMCID: PMC6368367
Gaynes, B. N., Lux, L., Gartlehner, G., Asher, G., Forman-Hoffman, V., Green, J., Boland, E., Weber, R. P., Randolph, C., Bann, C., Coker-Schwimmer, E., Viswanathan, M., & Lohr, K. N. (2020). Defining treatment-resistant depression. Depression and Anxiety, 37(2), 134-145. https://doi.org/10.1002/da.22968 PMID: 31638723
Johnston, K. M., Powell, L. C., Anderson, I. M., Szabo, S., & Cline, S. (2019). The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature. Journal of Affective Disorders, 242, 195-210. https://doi.org/10.1016/j.jad.2018.06.045 PMID: 30195173
McAllister-Williams, R. H., Arango, C., Blier, P., Demyttenaere, K., Falkai, P., Gorwood, P., Hopwood, M., Javed, A., Kasper, S., Malhi, G. S., Soares, J. C., Vieta, E., Young, A. H., Papadopoulos, A., & Rush, A. J. (2020). The identification, assessment and management of difficult-to-treat depression: An international consensus statement. Journal of Affective Disorders, 267, 264-282. https://doi.org/10.1016/j.jad.2020.02.023 PMID: 32217227
Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I. (2014). A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatric Services, 65(8), 977-987. https://doi.org/10.1176/appi.ps.201300059 PMID: 24789696
National Health Service. (2023, July 5). Treatment - Depression in adults. NHS. https://www.nhs.uk/mental-health/conditions/depression-in-adults/treatment/
National Institute for Health and Care Excellence. (2022). Depression in adults: Treatment and management (NICE guideline NG222). https://www.nice.org.uk/guidance/ng222
National Institute of Mental Health. (2024). Depression (NIH Publication No. 24-MH-8079). U.S. Department of Health and Human Services, National Institutes of Health. https://www.nimh.nih.gov/health/publications/depression
Sforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., et al. (2022). A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry, 27(3), 1286-1299. https://doi.org/10.1038/s41380-021-01381-x PMID: 34907394 · PMCID: PMC9095475